Precautions for use of Epcoritumab

In clinical studies of Epcoritumab (Epcoritamab), the more common precautions may include cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, infection, cytopenia, embryo-fetal toxicity, etc. The drug should be discontinued and resumed at a reduced dose after recovery, or permanently discontinued depending on the severity.

1. Cytokine release syndrome (CRS): includes severe or life-threatening reactions. In LBCL and FL patients who experienceCRS, signs and symptoms include fever, hypotension, hypoxia, dyspnea, chills, and tachycardia. Initiate treatment according to an escalating dose regimen of icarelatumumab. Administer pre-treatment medications to reduce the risk of CRS and monitor patients accordingly for potential CRS. At the first sign or symptom of CRS, the patient is immediately assessed for the need for hospitalization and managed according to current practice guidelines, with supportive care as appropriate. Patients who develop CRS (or other adverse reactions that impair consciousness) should be evaluated and advised not to drive and operate heavy or potentially hazardous machinery until the problem is resolved.

2. Immune effector cell-associated neurotoxic syndrome (ICANS): clinical manifestations include but are not limited to confusion, somnolence, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus. Episodes of ICANS can occur simultaneously with CRS, after resolution of CRS, or in the absence of CRS. Monitor patients for potential ICANS after icorelatumumab. At the first signs or symptoms of ICANS, assess the patient immediately and provide supportive care based on severity. Patients who develop ICANS signs or symptoms or any other adverse effects that impair cognition or awareness should be evaluated, including potential neurological evaluation, and patients at increased risk should be advised not to drive or operate heavy or potentially hazardous machinery until the problem is resolved.

3. Infection: Before and during treatment with icorelatumumab, monitor the patient for signs and symptoms of infection and provide appropriate treatment. Avoid the use of icorituzumab in patients with active infection. Offer PJP prophylaxis before initiating icarelatumumab; consider initiating herpes virus prophylaxis before initiating icarelatumumab.

4. Cytopenia: including neutropenia, anemia and thrombocytopenia. Monitor complete blood counts throughout treatment. Consider prophylactic administration of granulocyte colony-stimulating factor.

5. Embryo-fetal toxicity: According to its mechanism of action, icorelatumumab may cause harm to the fetus when used in pregnant women. Inform pregnant women of potential risks to the fetus. Advise females of reproductive potential to use effective contraception during treatment with icarelatumumab and for 4 months after the last dose.

In summary, although the use of icorelatumumab brings new hope for the treatment of hematological tumors, its potential adverse reactions and precautions cannot be ignored. The medical team needs to provide comprehensive monitoring and support during patient treatment to ensure patient safety and treatment effectiveness, while improving patient compliance and satisfaction with treatment.

Reference materials:https://www.drugs.com/epcoritamab.html